OPKO Completes Patient Recruitment in First Phase 3 Trial of RayaldyTM

OPKO Health, Inc. , has completed patient recruitment in the first phase 3 trial of Rayaldy TM to treat patients with secondary hyperparathyroidism , stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131115005074&newsLang=en&ndmConfigId=1000639&vnsId=41